Report Summary2018 Healthfor Humanity
ReportProgress in Citizenship & Sustainability

2018 Health for Humanity ReportStatement from Chairman & CEO
Dear Johnson & Johnson
Stakeholders,2018 marked a meaningful anniversary for
our Company.
Seventy-five years ago, we enshrined one ofour most enduring values into Our Credo:
to put the needs and wellbeing of those we
serve first. By always prioritizing those we
serve — something we’ve done since ourfounding — we’ve grown from a purveyor
of surgical dressings to the largest broadly
based healthcare company in the world.
At Johnson & Johnson, we believe we’reuniquely positioned to bring together
science, people, technology and the ideas
needed to profoundly change the trajectoryof health for humanity. That scale and reachcome with a huge sense of responsibility— every decision we make can have anenduring impact across the globe.
Our 2018 Health for Humanity Report isan invitation for you to experience thework we do. You’ll see how our ethos ofresults, transparency and accountability
runs through our key focus areas: better
health for the whole world, investing in
our people, responsible business practices
and safeguarding the environmental healthof our planet. Living by these values is
how we’ve helped to address some of thegreatest healthcare needs in modern history
while delivering long-term value for all the
stakeholders we serve.
The stakes continue to get higher. A rising
middle class, now in the billions aroundthe globe, is demanding quality, accessible
healthcare in unprecedented ways. Our
increasingly aging population is redefining

standards of care. Scientific advances
and technological disruption give us theopportunity and means to constantly
innovate. And the health impacts of climatechange provide the urgency for moreaction.

lines of healthcare. This year, we expandedthat commitment by joining the Health for
All alliance to ensure that 450,000 frontline
healthcare workers around the world get
the training they need.

At Johnson & Johnson, we know thatmeeting those challenges head on means
addressing disease along the entire
continuum of health: from prevention tointerception to cure. We’re making great
progress on our preventive HIV and Ebola
vaccines. As a committed partner in the
global fight against tuberculosis (TB), we’redelivering on our Health for Humanity 2020
Goal to treat the disease by increasing
access to our multidrug-resistant TB
therapy, bedaquiline.

However, none of these achievements
would be possible without our incredible
global workforce. As part of our 75th
anniversary enhancement of Our Credo,
we emphasized our commitment to always
creating a diverse culture of respect,
inclusion and belonging. And, as always,
we continue our push to have one of thehealthiest workforces in the world by
supporting our employees with everythingfrom best-in-class health programs toinvesting in their personal and professional
growth.

You can also see our commitment toexpanding access in our second annual
Janssen U.S. Transparency Report. It details
all the ways we’re working to secure andexpand patient access while leading in
our commitment to visible, accountable
and responsible drug pricing practices in
the United States. Globally, we make thesame commitment to expand access and it
helped land us a #3 position on the Accessto Medicine Index.

Putting the needs of those we serve
first also means protecting our sharedenvironment and natural resources. Our
Consumer business segment joined 240
other organizations in the New Plastics
Economy Global Commitment to tackle
the urgent environmental challenge ofplastic waste. This initiative expands upon
our broader organizational commitment toadvance environmental sustainability in ourown operations and in our supply base.

We recognize that we cannot solve all thepressing healthcare challenges alone andare proud to work in close partnership withhealthcare organizations around the world.
In sub-Saharan Africa, for example, we’repiloting a series of collaborations to create
an affordable, scalable quality care modelfor the treatment of severe mental illness.
That same collaborative spirit informs muchof our philanthropic investment. Take ourhistorical support of workers at the front

To ensure we’re always investing for the
future and keeping the long-term view,
we’re participating in important initiatives
like the Embankment Project for Inclusive
Capitalism, CECP’s Strategic Investor
Initiative and the U.S. Business Roundtable.
With these expert partners, we’re helping
to shift the conversation in the financial
markets toward a long-term view andmeasurement of the value to society that abusiness like ours creates.

Alex Gorsky meeting with employees on his visit
to Australia.

Our Health for Humanity Reportdemonstrates how we’ve used our history
of innovation to change the health andwellbeing of everyone we serve. Our unique
mix of talent, know-how and values is how
we’ll change the world — not just as leadersin healthcare, but also as global citizens
and champions of transforming lives andcommunities.
In the meantime, we recognize there isalways more to do, and we welcome thechallenge to make sure we’re even moresustainable, innovative and responsible
moving forward.

Alex Gorsky
Chairman, Board of Directors
and Chief Executive Officer2

2018 Health for Humanity Report

Sustainability Approach▪▪ Engaging with our stakeholders tounderstand and address their views andexpectations.
We focus our citizenship and sustainability
efforts where we believe Johnson & Johnson
can achieve the greatest impact byleveraging the power of our people,
expertise and global partnerships.

At Johnson & Johnson, we blend heart,science and ingenuity to profoundlychange the trajectory of health forhumanity. This aspiration includes positively
impacting patients and all others who
use our products, as well as the healthof our employees, our communities andthe planet. We seek to provide solutions
for some of the world’s most pressing
global public health challenges andwork collectively — within our walls andexternally with partners — to advancebetter health for all. Our citizenship andsustainability approach is inextricably
linked to our vision of a world where ahealthy mind, body and environment arewithin reach for everyone, everywhere. It's
based on:▪▪ Continuing to raise the bar for ourselves
by setting five-year public commitments
to both improve our performanceand demonstrate leadership acrossenvironmental, social and economic
topics relevant to our business;▪▪ Measuring our transparency about ourprogress against public commitments;▪▪ Continuing to strengthen ourgovernance of citizenship andsustainability activities across theEnterprise;▪▪ Conducting periodic Priority Topics
Assessments to ensure that in the everchanging business environment weprioritize and focus on issues that are
relevant to our stakeholders and can
impact our business;

Our Health for Humanity 2020 Goals arealigned with our Company’s purpose andreflect the areas where our stakeholders
expect us to lead. We believe that achieving
these goals is integral to Johnson & Johnson’slong-term success, and we consider them
to be the Key Performance Indicators of
our citizenship and sustainability approach.
Johnson & Johnson is also committed tosupporting implementation of the United
Nations Sustainable Development Goals
through both our Health for Humanity 2020
Goals and a separate set of commitments
across five key issue areas where we are
uniquely positioned to create sustainable
and scalable impact.

More
Resources
Learn more about ourprogress in citizenshipand sustainability in ourfull 2018 Health for
Humanity Report
Watch our 2018 Health for
Humanity Report Year in Brief
Highlights Video
Review the Health for
Humanity 2020 Goals
Progress Scorecard
Review our UN SDGs
Progress Scorecard andSustainable Development
Goals webpage

3

2018 Health for Humanity Report2018 Year in Brief
Highlights of the year
SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir
alafenamide), the first and only complete darunavir-based
single-tablet regimen to treat HIV-1 approved by the U.S. FDA

Advanced development of arevolutionary CAR-T therapy
for multiple myeloma#3 on Access to Medicines Index

Broader use of bedaquliline to treat
MDR-TB patients recommended by theWorld Health Organization

Launched a pilot program in Rwanda to
improve access to mental healthcare

Celebrated Our Credo
75th Anniversary

Johnson & Johnson Consumer Inc. joined the
New Plastics Economy Global Commitment

Expanded partnership with UNICEF with a$10 million pledge

Launched new JOHNSON'S Baby

Impact madeOur Patients & Consumers

Our Employees

Our Communities & Planet

Our Shareholders

38,994

16,343

104,479

56

patients provided access to
MDR-TB treatment

51,503

patients provided accessto HIV treatment

employees trained in the principles of
ENERGY FOR PERFORMANCE

44.2%

of Manager and above talent movementthat was across function,
country or sector lines*

health workers educated in 67 countries

consecutive years of dividend increases

31%$10,775M

electricity use from renewableenergy sources

invested in R&D* Represents the proportion of employees in Manager and above job categories who in their career progression movement (including upward promotion, downward demotion, or lateral transfer) crossed
function, country or business segment lines.

42018 Health for Humanity Report

Better Health for All – World Without Disease
As a global healthcare leader,Johnson & Johnson is at the forefront ofaddressing the world’s most intractablediseases. In 2018, we advanced actions to
reduce the burden of prominent diseases
and are on track against our publishedtargets, advancing better health for adults
and children around the world.

Making HIV History
We continued our advances on several
fronts to combat the spread of HIV and,more importantly, to eliminate the disease
through an investigational preventive
vaccine. In 2018, we embarked upon our
Imbokodo study — a historic Mosaicbased Preventive Vaccine Regimen for HIV
study — in five southern African countries
in an effort to identify mechanisms toprevent the spread of HIV and lead theway to developing a global vaccine
effective against the multiple strains of
the virus. We advanced several programs
and partnerships in different countries toincrease access to HIV treatment or raiseawareness. An example is “DREAMS, Thina
Abantu Abasha,” which we launched inSouth Africa as a youth-led initiative aimed
at empowering youth to substantiallyreduce the rate of HIV infections.

“

We are in a golden age in
HIV vaccine science. Currently
we are exploring two different
active HIV vaccine strategies
as well as evaluating whethera trial using neutralizing
antibodies can protect against
HIV. In the next four years, wehave the potential to change
the game, and bring valuable
tools to the public to protect
communities from HIV.

”

Professor Glenda Gray
President & CEO of the South African
Medical Research Council (SAMRC)
and Protocol Chair of the
Imbokodo study

10-year initiative, with the goal of saving an
estimated 1.8 million lives and preventing
12 million new infections, working
with partners to improve detection ofundiagnosed cases of TB, broaden accessto bedaquiline and accelerate R&D to
discover next-generation TB treatments.

Eradicating Tuberculosis

Combating Neglected Tropical
Diseases

In 2012, Johnson & Johnson brought
forward SIRTURO (bedaquiline), the firstnovel TB antibiotic in nearly half a century.
Since then, we have partnered extensively
in high-burden countries to provide accessto and ensure appropriate use of ourtreatment, and to raise awareness about
TB more broadly. In 2018, we announced a

We continue to target resources tocombat Neglected Tropical Diseases(NTDs) through R&D, product donations
and partnerships. To facilitate additional
research, Janssen shares 80,000 chemicalcompounds from its molecular library withthe global research community to help
collaborators accelerate treatment andprevention of TB, malaria, NTDs, and otherdiseases common in the developing world.
We have met our commitments of donating
200 million doses annually and developing
a new chewable, child-friendly formulationof mebendazole to treat soil-transmitted
helminthiasis or intestinal worms. We
continued our work to address dengue.

Transforming Mental Healthcare
In August 2018, we entered into acomprehensive partnership with the
Rwanda Ministry of Health to strengthen
and expand access to quality mental
healthcare in that country, supporting
research, improving affordability andavailability of essential medicines to treat
schizophrenia, and building capacity inmental healthcare to more accurately
diagnose and treat patients. We also
engaged in several other initiatives toaddress mental health.

Global Health Security &Preventing Pandemics
In 2018, we announced that Janssen
Vaccines & Prevention will participate in a
new collaboration with the UK government
and multiple partners from academia andindustry that will result in the UK’s firstever dedicated Vaccine Manufacturing
and Innovation Centre. Our work on newprevention, treatment and care solutions forpandemic influenza, Ebola, Zika and malaria
continued through 2018.

Overcoming Antimicrobial
Resistance
We are working on multiple fronts tofulfill our Antimicrobial Resistance (AMR)
Roadmap commitments. We currently
provide 22 antimicrobial medicines(including antiviral medicines) in 114
countries, of which seven are listed on theWorld Health Organization’s Model List of
Essential Medicines. Much of our work is
focused on multidrug-resistant tuberculosis(MDR-TB), given our long legacy of fighting
TB and as MDR-TB alone accounts for athird of AMR-related deaths.

5

2018 Health for Humanity Report

Better Health for All – Access, Innovation & Community Health“Johnson & Johnson has
been consistently a leader
in the last four Access to
Medicine Indices, bringing
forward valuable treatments
in areas such as TB andrecently addressing mental
health in low- and middleincome countries. Its Global
Public Health Unit is a model
among the industry on accessplanning and results for several
therapeutic areas, constantly
challenging itself to do more.
As a company with a strong
R&D pipeline and a global
network capable of further
addressing the needs ofthose in the most challenging
countries, we encourage
Johnson & Johnson to takeeven more action.

”

Jay Iyer
Executive Director, Access to Medicine
Foundationneed Janssen medicines get access to themin the United States. We also prioritize
helping patients gain access to informationand solutions that can improve adherence
to treatment regimens and co-creating
treatment solutions that meet their needs.

Innovating For Better Health
We innovate for better health by combining
a strong internal focus on R&D withstrategic external partnerships thatemphasize local solutions to meet different
healthcare needs across the world. We fuelinnovation through hiring top scientists andmedical and technology experts to advanceour product pipeline, investing in our fourglobal Innovation Centers, accelerating
innovation through JLABS, our network ofopen innovation health sciences incubators,
and managing our corporate venture fundin the life sciences industry.
Innovation extends beyond products —for example, to digital tools to support
patients in clinical trials and connected
health technology innovation that empower
patients, caregivers, and providers.

Strengthening Health Systems
Enhancing Access to Healthcare
As the world’s largest healthcare company,
we are committed to improving accessto our innovative medicines, vaccines,
devices and diagnostics in all markets.
We continue to uphold our access-driven
pricing strategies, and Janssen publishes
an annual U.S. Transparency Report
describing how we invest our resources,
price our medicines, and help people who

We support global Universal Health
Coverage and advanced several actionsin 2018 to help make this become reality.
We maintain a range of partnerships, inmost cases funded by grants throughour Johnson & Johnson Foundation, that
help engage young people in science andnursing or midwifery education. In 2018,
we also continued initiatives to further the
adoption of a value-based care approach,including supporting ongoing debate
through dedicated forums in Singapore.

Contributing to Community
HealthOur Credo defines the concept that “We
are responsible to the communities inwhich we live and work and to the worldcommunity as well.” At Johnson & Johnson,
we fulfill this obligation by actively
engaging in our communities across theglobe. We support the people at the front
lines of delivering care, so that communities
can more effectively address the healthneeds of the world’s most vulnerable
people. Our giving, products, innovation,and business initiatives help create a betterworld and environment for people aroundthe globe.
Our programs, platforms and solutions aredeveloped through global leadership andregional and country-level colleagues tomeet community needs while aligning withenterprise-wide priorities where
Johnson & Johnson has unique knowledge
and skills to make a difference.
We mobilize partners for the benefit of
our communities through partnership,
financial support, activation of our large
employee base and advocacy for priority
health issues. We work with our community
partners in a collaborative spirit, based on
mutual trust and aligned values.
Our employees are actively involved involunteering in our community initiatives,
as well as participating in other community
engagement programs.
We also support international relief
partners and local affiliates with consumer,
pharmaceutical, and medical products intimes of disaster.

Accelerating Innovation
Through JLABS▪▪ JLABS has supported over 450
companies over more than 6
years, a 44% increase in 2018
over 2017▪▪ $11.6 billion in financing secured
in 2018 (23% more than in 2017)▪▪ 12 companies now publicly
traded▪▪ 88% of JLABS companies are
currently in business or acquired6

2018 Health for Humanity Report

Our People“

Our culture is rooted in
the values embodied in Our
Credo, which calls on us to
support our employees acrosstheir whole lives — spiritual,mental, physical and financial.
Guided by this principle,
we provide thousandsof individuals with theopportunity to build a variedand diverse career acrossthe full spectrum of humanhealth and the opportunity
to help advance our purposeof changing the trajectory ofhealth for humanity.

”

Peter M. Fasolo
Executive Vice President, Chief Human
Resources Officer
Johnson & Johnson

We owe our success to the thousands ofJohnson & Johnson employees who are
passionate about our mission to change
the trajectory of health for humanity.
People join Johnson & Johnson to build
a purpose-driven career that makes adifference; they stay with us to help create
healthier lives and improve the wellbeingof those we serve in our communities
around the world. In 2018, we drove several
programs to engage, empower and inspire
our employees, and to help them develop
personally and professionally. We also

created opportunities to help employees
improve their health and wellbeing and tostay safe at work.

Attracting the Most Talented
PeopleTo continue to attract and retain the best
and most diverse people, we launchedthe Hire.jnj.com platform globally in
2018, providing data-driven analytics andinnovative tools as the basis for a faster,transparent, more agile process for hiring
candidates.

Creating Unique Career
Opportunities
Our development programs include onthe-job training, online courses, workshops
and other experiential training. In 2018, welaunched a global personal development
platform called MyDevelopment tohelp employees build a healthy career.
We also delivered critical new learning
resources through our on-demand, digitalplatform, Leadership Navigator, to raise theperformance and skill level of our people
leaders around the globe.

Engaging, Empowering &Inspiring
In 2018, Johnson & Johnson marked
the 75th anniversary of Our Credo andengaged employees in activities centeredon opportunities to better live Our Credo
through daily actions. More than 30,000
employees around the world participatedin the first annual Credo Day celebration
and brought the Credo spirit to their local
communities.
We continued our popular TEDxJNJ events
where Johnson & Johnson employees sharepersonal or professional stories as a sourceof inspiration for others. In 2018, we held
20 TEDxJNJ events across 13 countries,
bringing our total to date to 76 events in 19
countries.
We continued to engage our employees
in our communities, for example, our
Global Pro Bono program expanded to 21
participants, who shared their skills to help
seven nongovernmental organizations in
Latin America better reach their goals.

Advancing Diversity & Inclusion
To demonstrate our commitment andprogress in advancing diversity andinclusion as part of our DNA at
Johnson & Johnson, we launched acampaign to showcase the inclusive
Johnson & Johnson community to internaland external audiences. Learn more here.

Providing Safe Workplaces
We held our first-ever enterprise-wide
Safety Month to provide a focused periodof awareness, education and collaboration
for improved safety practice, engaging fromacross the Company in our offices, in thefield, in a lab, or on the production floor.

Championing Health & Wellness
With HealthForce 2020, our integrated
program to support healthy choices andhealthier lives, we continue to promote
ENERGY FOR PERFORMANCE training
for all employees. Our HEALTHY & ME
digital health app is available to most of ouremployee population in 72 countries and in
16 languages.
In 2018, we announced a new global
employee exercise-program reimbursement
to help cover the cost of fitness center
membership fees or other exercise activity.

Partnered with 230 organizations to advancethe training, skills-building and leadershipdevelopment of 104,479 of health workers

6,327
Midwives

37,352
Nursesin 67

Countries

7

2018 Health for Humanity Report

Responsible Business Practices“

JOHNSON'S fragrances
are designed specifically fordelicate and sensitive skin, so
we design products to avoid
harsh ingredients and wellknown fragrance allergens.
Our baby fragrances have beenreviewed by both independentgroups and safety experts— and for the first time are
all listed on the JOHNSON'S
website.

”Homer Swei
Director of Product StewardshipJohnson & Johnson Consumer Inc.

Responsible business practices serve as thefoundation of our Company’s success andare imperative to protecting the broader
healthcare system and the communities inwhich we live and work.

Product Quality, Safety &Reliability
We maintain a proactive quality excellence
culture throughout the Enterprise,
underpinned by our enterprise-wide
Quality and Compliance Core Objective
and supported by training, monitoring,risk assessments and audits. In 2018, we
maintained and reinforced our quality
programs. We also enhanced productsafety processes, leveraging the power ofbig data and analytics to support informed

decision making on treatments. We
invest in a strong anti-counterfeiting andbrand protection strategy to protect ourcustomers and patients from the impact ofillicit trade.
We improved transparency in consumer
products — for example, we redesigned
all our JOHNSON’S washes, lotions andhaircare products and reduced the numberof ingredients in our portfolio by more than
50%, disclosing 100% of the ingredients inthese products.

Ethics & Transparency
The Code of Business Conduct and HealthCare Compliance policies set forth ourCompany’s values, which apply to all
employees worldwide. We take a strong
stance against bribery and our policies
follow recognized anti-bribery and anticorruption laws and regulations. Our
Credo Hotline offers a secure channel foranonymous reporting and serves as ouranonymous whistle-blowing mechanism,
providing a conduit for all to reportpotential violations. In 2018, we updated
our Statement on Human Rights following arigorous internal review process.

Responsible Supply Base
Our Responsibility Standards for Suppliers
set forth the expectations we have of all
Johnson & Johnson suppliers. We continue
to evolve our processes to monitor suppliercompliance with these Standards, using arisk-based approach through assessments
and on-site audits. In 2018, we achieved
our annual target of enrolling 61% of our

suppliers, representing our top spend in our
Sustainable Procurement Program. We arealso active promoters of supplier diversity— for example, in more than 20 countries,
we partner with WeConnect International,
a global network supporting women-owned
businesses.

8

2018 Health for Humanity Report

Environmental Health“With this decision toaccelerate our sustainability
goals, Johnson & Johnson
Consumer Inc. is
acknowledging the everincreasing urgency of the issueof plastic waste — and our own
responsibility to work towards
innovative solutions.

”

Paulette FrankWorldwide Vice President,
Environmental Health, Safety &Sustainability
Johnson & Johnson

Energy & Carbon Efficiency

Waste & Water Management

We focus our energy and carbon efficiency
work on three main areas: reducing energy
demand and maximizing energy efficiency
in our operations; shifting to low-carbon
and renewable energy sources to meetthe remaining demand; and improving our
influence over emissions in our value chain.
Our science-based Scope 1 and Scope 2
absolute GHG emission reduction targets
commit us to ambitious reductions through2050. We are continuously developing
our investment and operations towards
our aspiration of powering 100% of ourfacilities with renewable energy by 2050,
while advancing green building certification
for new buildings and renovations. Amongothers, we achieved LEED Platinum andGold certifications in China and Colombia
in 2018.

At Johnson & Johnson, we aim tominimize our impacts on the planet
through responsible use of water andminimizing waste generation at source,
while increasing sustainable managementof waste. We measure water risk with ourproprietary risk assessment model for water
stress. In 2018, we implemented several
initiatives at our plants to systematically
avoid waste or reduce waste to landfill.

Product Sustainability
In 2018, Johnson & Johnson Consumer Inc.
became a signatory to the New Plastics
Economy Global Commitment, thereby
committing to use more recycled materials
in packaging, reduce reliance on singleuse packages, and ensure that 100% of

plastic packaging be reusable, recyclable orcompostable via design, partnerships, andinvestments by the year 2025.
EARTHWARDS is our approach forencouraging the development of moresustainable products. Focusing on the
lifecycle areas with the highest potential
impact, we prioritize improvements forthe largest possible impact reduction.
When a product achieves at least threesignificant improvements across our seven
impact areas, a board of external experts
determines if it warrants EARTHWARDS
recognition.
Johnson & Johnson Consumer Inc. also
adopted the How2Recycle label, startingwith many of our JOHNSON'S products,
including baby lotion, baby shampoo andbaby wash.

The label helps make recycling easier by
providing specific instructions on how eachproduct can be recycled.

92018 Health for Humanity Report
Progress in Citizenship & Sustainability

Contact us
WW-Corporate-Governance@jnj.com
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
healthforhumanityreport.jnj.com
jnj.com

Front Cover: Every day 1,000 adolescents girls and young women are infected with HIV in sub-Saharan Africa, having a disproportionate impact on theirlives and preventing them from fulfilling their potential. That’s why we launched DREAMS Thina Abantu Abasha (Zulu for ‘We the Youth”), a youth-led andimplemented peer-to-peer program, with PEPFAR and UNFPA in some of the worst HIV hotspots to reduce HIV infections among girls 15 – 24 years old. Thisis part of our longstanding Company-wide commitment to make HIV history. Learn more at www.jnj.com/hiv. Photo by Jonathan Burton.